Condition

Unresectable Lung Small Cell Carcinoma

ClinicalTrials.gov condition label

Clinical trials4
Recruiting0
Common interventions20
Lead sponsors shown2

Clinical trials

4 shown
Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT TrialNCT05339022 · 2022-04-14
COMPLETED
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic CancerNCT04514497 · 2021-10-20
ACTIVE_NOT_RECRUITING
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsNCT02498613 · 2016-08-31
ACTIVE_NOT_RECRUITING
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryNCT02595931 · 2016-07-22
ACTIVE_NOT_RECRUITING

Common interventions

Biospecimen CollectionPROCEDURE2Computed TomographyPROCEDURE2Irinotecan HydrochlorideDRUG218F-FluoromisonidazoleOTHER1BerzosertibDRUG1Best PracticeOTHER1Biopsy ProcedurePROCEDURE1Biopsy SpecimenPROCEDURE1Cediranib MaleateDRUG1ElimusertibDRUG1Exercise InterventionOTHER1Laboratory Biomarker AnalysisOTHER1Magnetic Resonance ImagingPROCEDURE1OlaparibDRUG1Physical TherapyPROCEDURE1Positron Emission TomographyPROCEDURE1Quality-of-Life AssessmentOTHER1Questionnaire AdministrationOTHER1Relaxation TherapyPROCEDURE1Topotecan HydrochlorideDRUG1

Trial status mix

ACTIVE_NOT_RECRUITING3
COMPLETED1

Phase mix

PHASE12
NA1
PHASE21

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.